Enfortumab vedotin for cisplatin-ineligible urothelial cancer
Mené sur 89 patients atteints d'un carcinome urothélial de stade localement avancé ou métastatique ne pouvant être traité par cisplatine (durée médiane de suivi : 13,4 mois), cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité de l'enfortumab vedotin après un traitement par inhibiteur de PD-1 ou PD-L1
Locally advanced or metastatic urothelial carcinoma is usually incurable, with few treatment options. Cisplatin-based chemotherapy is the first-line standard of care. However, about 50% of these patients are ineligible for cisplatin therapy and face suboptimal treatment options. PD-1 or PD-L1 inhibitors have been approved as first-line therapy for cisplatin-ineligible patients whose tumours express high levels of PD-L1, based on a meaningful and durable clinical response, although objective responses occur in less than 30% of unselected patients. In the event of progression after first-line immunotherapy, these patients have scarce treatment options and therefore constitute a critical population with poor prognosis.
The Lancet Oncology , commentaire, 2020